4519N Stock Chart & Stats
$825.61
$0.00(0.00%)
At close: 4:00 PM EDT
$825.61
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$732.85 - $962.10
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$1.31T
Enterprise Value$9.39T
Total Cash (Recent Filing)$869.00B
Total Debt (Recent Filing)$16.14B
Price to Earnings (P/E)21.7
Beta0.78
Next Earnings
Feb 04, 2027EPS Estimate
9.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)306.08
Shares Outstanding1,679,057,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.60
Price to Book (P/B)6.70
Price to Sales (P/S)10.78
P/FCF Ratio43.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$955.57Price Target Upside15.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)36.32
Revenue Forecast (FY)$163.30B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityChugai’s exceptionally high gross, operating, and net margins indicate strong pricing power and an attractive product mix. This profitability provides substantial resources to fund research, commercial expansion, and shareholder returns while supporting resilience through changes in product demand.
Conservative Balance SheetMinimal leverage and strong equity growth give Chugai considerable financial flexibility without dependence on borrowing. High returns on equity show that the company is using its capital efficiently, strengthening its ability to fund pipeline investment and withstand industry volatility.
Pipeline And Product MomentumDivarasib’s positive Phase III efficacy and planned regulatory filing add a potentially important oncology growth driver beyond the existing portfolio. Combined with multiple advancing projects, this supports longer-term product renewal and expands Chugai’s strategic pipeline.
Bears Say
Pricing And Generic PressureDrug price revisions and generic competition can structurally erode revenue and margins for established products in Japan. These pressures may require continued launches and innovation merely to offset declines, increasing the importance of successful pipeline execution for sustained growth.
Free Cash Flow Growth DeclineAlthough absolute cash generation remains strong, the recent decline in free cash flow growth indicates that more cash is being absorbed by investment or working-capital movements. If sustained, this could reduce funding flexibility for development, licensing, and shareholder distributions.
Pipeline AttritionDiscontinuing a clinical program removes a potential future revenue source and highlights the scientific uncertainty inherent in drug development. Repeated late-stage setbacks could increase reliance on existing products and raise the execution burden on the remaining pipeline.
Chugai Pharmaceutical Co News
4519N FAQ
What was Chugai Pharmaceutical Co Ltd’s price range in the past 12 months?
Chugai Pharmaceutical Co Ltd lowest stock price was $732.85 and its highest was $962.10 in the past 12 months.
What is Chugai Pharmaceutical Co Ltd’s market cap?
Chugai Pharmaceutical Co Ltd’s market cap is $1.31T.
When is Chugai Pharmaceutical Co Ltd’s upcoming earnings report date?
Chugai Pharmaceutical Co Ltd’s upcoming earnings report date is Feb 04, 2027 which is in 97 days.
How were Chugai Pharmaceutical Co Ltd’s earnings last quarter?
Chugai Pharmaceutical Co Ltd released its earnings results on Oct 27, 2026. The company reported $11.002 earnings per share for the quarter, beating the consensus estimate of $9.072 by $1.931.
Is Chugai Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Chugai Pharmaceutical Co Ltd’s price is currently Undervalued.
Does Chugai Pharmaceutical Co Ltd pay dividends?
Chugai Pharmaceutical Co Ltd does not currently pay dividends.
What is Chugai Pharmaceutical Co Ltd’s EPS estimate?
Chugai Pharmaceutical Co Ltd’s EPS estimate is 9.22.
How many shares outstanding does Chugai Pharmaceutical Co Ltd have?
Chugai Pharmaceutical Co Ltd has 1,679,057,600 shares outstanding.
What happened to Chugai Pharmaceutical Co Ltd’s price movement after its last earnings report?
Chugai Pharmaceutical Co Ltd reported an EPS of $11.002 in its last earnings report, beating expectations of $9.072. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Chugai Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in MX:4519N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chugai Pharmaceutical Co Ltd
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
4519N Company Deck
4519N Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall. Revenue and core operating profit grew substantially, the company expects to exceed its full-year forecast, overseas products and royalties performed well, and the pipeline delivered approvals, filings, positive clinical readouts, and important progress for Hemlibra and Divarasib. The main challenges were pricing and generic pressure, higher costs, one-time domestic shipment timing, discontinued GYM329 obesity and LUNA18 programs, selected product declines, and reduced cash following large tax and special dividend payments. Highlights significantly outweighed lowlights.View all MX:4519N earnings summaries4519N Stock 12 Month Forecast
Average Price Target
$955.57
▲(15.74% Upside)